

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

**UPDATED INFORMATION ON THE GROUP'S PRODUCT  
MOXIFLOXACIN HYDROCHLORIDE EYE DROPS**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that Moxifloxacin Hydrochloride Eye Drops (specifications: 0.5% (3ml:15mg), 0.5% (5ml:25mg)) submitted by Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, a wholly-owned subsidiary of the Company, have been approved by China National Medical Products Administration, with drug approval numbers of H20256128 and H20256129.

Moxifloxacin hydrochloride is the fourth-generation quinolone antibiotic with broad-spectrum antibacterial activity. Moxifloxacin hydrochloride eye drops are indicated for the treatment of bacterial conjunctivitis caused by susceptible microorganisms such as *Staphylococcus aureus*, *Haemophilus influenzae*, and *Chlamydia trachomatis*. The product is preservative-free, avoiding the cytotoxic effects of antimicrobial preservatives on ocular tissues, and is suitable for a wide range of patient populations. Currently, moxifloxacin hydrochloride eye drops have been listed in the Category B in the National Medical Insurance Drug List (2024 Edition).

The approval of this product will further expand the Company's ophthalmic portfolio and strengthen the Company's leading position in the field of ophthalmic anti-infective treatment. The Company will continue to advance the development of new products and provide comprehensive, high-quality therapeutic solutions for clinical use, which is expected to generate greater returns for the Company and its shareholders.

By Order of the Board

**The United Laboratories International Holdings Limited**

**Tsoi Hoi Shan**

*Chairman*

Hong Kong, 9 December 2025

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.